<i>Background and Objectives</i>: This review summarizes the pathological and biological framework of HER2-low and HER2-ultralow breast cancer and critically appraises the magnitude, direction, and determinants of HER2 variability under systemic therapy. The gene discussed is ERBB2; the disease is breast carcinoma.